Andrographis — Benefits Deep Dive

Andrographis paniculata is known across South and Southeast Asia as the "King of Bitters" (Maha-Tikta in Sanskrit, Chuan Xin Lian in traditional Chinese medicine), a name that reflects both its extraordinary bitterness and its premier status in traditional herbal pharmacopeias for fevers, infections, and liver disease. Its principal bioactive constituent is andrographolide, a labdane diterpene lactone present at 1-4% in the leaves and concentrated to standardized levels in modern extracts. Andrographolide is the molecular handle behind nearly every documented effect — from inhibition of NF-kB-driven inflammation, to potentiation of NK cell and macrophage activity, to hepatoprotection through Nrf2 induction, to direct interference with viral attachment and replication. Four benefit pages below explore the conditions where Andrographis produces its largest and best-documented clinical effects.

Deep-Dive Articles

Back to Table of Contents

Table of Contents

1. Deep-Dive Articles
2. Why Andrographis Produces Effects Across So Many Systems
3. Research Papers: Cold & Flu
4. Research Papers: Immune Modulation
5. Research Papers: Liver Protection
6. Research Papers: Anti-Inflammatory
7. Research Papers: Cross-Cutting (Mechanism, Pharmacology, Safety)
8. External Authoritative Resources
9. Connections

Why Andrographis Produces Effects Across So Many Systems

Many medicinal plants accumulate a wide variety of secondary metabolites and produce a wide variety of mild biological effects. Andrographis is unusual because the bulk of its activity is attributable to a single molecule, andrographolide (and its three lesser congeners: 14-deoxyandrographolide, neoandrographolide, and 14-deoxy-11,12-didehydroandrographolide). Andrographolide is a labdane-type diterpene lactone with an alpha,beta-unsaturated lactone (a "Michael acceptor") group that allows it to form covalent bonds with cysteine thiols on a small set of regulatory proteins. The three principal molecular targets explain most of the clinical effects:

1. NF-kB p50 subunit (Cys-62) — covalent modification of this cysteine blocks NF-kB binding to DNA at kappa-B promoter elements, shutting down transcription of TNF-alpha, IL-1-beta, IL-6, COX-2, iNOS, ICAM-1, and other inflammatory mediators. This is the mechanism behind the anti-inflammatory effects in arthritis and inflammatory bowel disease, and also a major contributor to its non-stimulatory immune-modulating profile.
2. Keap1 (cysteine residues) — andrographolide modifies cysteines on Keap1, releasing Nrf2 to translocate to the nucleus where it binds ARE (antioxidant response element) promoter regions and activates phase-II detoxification enzymes (glutathione synthesis, glutathione-S-transferase, NAD(P)H quinone oxidoreductase, heme oxygenase-1). This is the mechanism behind the hepatoprotection against chemical and drug-induced liver injury.
3. Viral attachment and replication proteins — andrographolide directly binds to viral spike proteins (demonstrated for HIV gp120, influenza hemagglutinin, dengue envelope) and to viral enzymes (HIV reverse transcriptase, influenza neuraminidase, dengue NS5 polymerase). These direct antiviral effects, combined with the upstream cytokine modulation, explain the benefit in viral upper respiratory tract infection.

Beyond these three principal targets, andrographolide also activates AMPK, inhibits HIF-1-alpha, and modulates the PI3K/Akt and JAK/STAT pathways — explaining the broader interest in andrographolide as a candidate drug scaffold in cancer, type-2 diabetes, and neurodegenerative disease. Several semi-synthetic andrographolide derivatives are in early clinical development as anti-inflammatory drugs, including DRF 3188 (Dr. Reddy's, ulcerative colitis) and AND-1 (oncology).

Pregnancy contraindication. Andrographis is a uterine stimulant and is contraindicated in pregnancy. Animal studies (rat, rabbit) document increased uterine contractions and abortifacient potential at doses corresponding to typical human therapeutic intake. The traditional Ayurvedic and Thai pharmacopeias both list pregnancy as an absolute contraindication, and modern regulatory bodies (European Medicines Agency Committee on Herbal Medicinal Products, Australia TGA) carry the same warning on Andrographis monographs. Women trying to conceive should also avoid Andrographis because of one rat study suggesting reversible reduction in male fertility (decreased sperm motility on high-dose extracts) and one observational signal of reduced female fertility. The herb is otherwise well-tolerated in non-pregnant adults and children over 4 at age-adjusted doses.

Back to Table of Contents

Research Papers: Cold & Flu

1. Coon JT, Ernst E (2004), systematic review of seven RCTs on Andrographis for uncomplicated URTI — PubMed: Coon & Ernst 2004 systematic review
2. Hu XY et al. (2017), meta-analysis of 33 RCTs and 7,175 patients on Andrographis for acute respiratory tract infection — PubMed: Hu 2017 meta-analysis
3. Kan Jang (Andrographis + Eleutherococcus) clinical trials in common cold (Caceres / Melchior series) — PubMed: Kan Jang URTI trials
4. Andrographolide and influenza neuraminidase inhibition — PubMed: Andrographolide and influenza
5. Andrographis paniculata for sore throat symptom reduction (Thamlikitkul 1991 Thailand trial) — PubMed: Thamlikitkul Thailand trial
6. Andrographis for sinusitis adjunct therapy — PubMed: Andrographis sinusitis
7. Andrographolide attenuates influenza A virus-induced lung injury in mice — PubMed: Andrographolide influenza lung injury
8. Standardization of andrographolide content in commercial Andrographis extracts — PubMed: Andrographolide standardization
9. Saxena RC, Singh R, et al. randomized double-blind controlled trial of Andrographis extract in uncomplicated upper respiratory infection — PubMed: Saxena RCT
10. Andrographis and respiratory syncytial virus inhibition in vitro — PubMed: Andrographolide RSV

Back to Table of Contents

Research Papers: Immune Modulation

1. Burgos RA et al. (2009), randomized double-blind placebo-controlled trial of Andrographis paniculata extract HMPL-004 in mild-to-moderate ulcerative colitis — PubMed: Burgos 2009 UC trial
2. Andrographolide enhances natural killer (NK) cell cytotoxicity — PubMed: Andrographolide NK cells
3. Andrographolide modulates the Th1/Th2/Th17 cytokine balance — PubMed: Andrographolide Th1/Th2/Th17
4. Andrographolide increases macrophage phagocytosis and intracellular killing — PubMed: Andrographolide macrophages
5. Andrographolide increases CD4+ T cell counts and CD4+/CD8+ ratio in HIV-infected patients (pilot study) — PubMed: Andrographolide CD4/CD8 HIV
6. HMPL-004 for active ulcerative colitis follow-up Phase II trial — PubMed: HMPL-004 Phase II
7. Andrographolide and dendritic cell maturation — PubMed: Andrographolide dendritic cells
8. Andrographis paniculata extract and lymphocyte proliferation assays — PubMed: Lymphocyte proliferation
9. Andrographolide for autoimmune disease (mechanistic review) — PubMed: Andrographolide autoimmunity review
10. Andrographolide-mediated suppression of cytokine storm in sepsis models — PubMed: Andrographolide cytokine storm

Back to Table of Contents

Research Papers: Liver Protection

1. Andrographolide activates Nrf2 / Keap1 antioxidant response element pathway — PubMed: Andrographolide Nrf2/Keap1
2. Andrographolide-induced protection against carbon tetrachloride (CCl4) hepatotoxicity — PubMed: Andrographolide CCl4
3. Andrographis paniculata and acetaminophen (paracetamol) hepatotoxicity reduction — PubMed: Andrographis paracetamol
4. Andrographolide protection against ethanol-induced liver injury — PubMed: Andrographolide ethanol liver
5. Andrographolide and aflatoxin B1 hepatocarcinogenesis — PubMed: Andrographolide aflatoxin
6. Andrographis paniculata as a cholagogue (bile-flow stimulant) — PubMed: Andrographis cholagogue
7. Andrographolide inhibition of CYP1A1 and CYP2B1 carcinogen bioactivation — PubMed: Andrographolide CYP P450
8. Andrographolide upregulates glutathione synthesis and glutathione-S-transferase — PubMed: Andrographolide glutathione
9. Andrographolide in non-alcoholic fatty liver disease (NAFLD) animal models — PubMed: Andrographolide NAFLD
10. Comparison of Andrographis with silymarin (milk thistle) for hepatoprotection — PubMed: Andrographolide vs silymarin

Back to Table of Contents

Research Papers: Anti-Inflammatory

1. Andrographolide as a covalent inhibitor of NF-kB p50 (Xia et al., Cys-62 modification) — PubMed: Andrographolide NF-kB p50
2. Andrographis paniculata in rheumatoid arthritis (Burgos 2009 trial) — PubMed: Burgos RA trial
3. Andrographolide inhibits TNF-alpha, IL-1-beta, IL-6 cytokine production — PubMed: Andrographolide TNF/IL-1/IL-6
4. Andrographolide downregulates COX-2 and iNOS expression — PubMed: Andrographolide COX-2/iNOS
5. Andrographolide in osteoarthritis (knee, hand) human trials — PubMed: Andrographolide osteoarthritis
6. Andrographolide and ankylosing spondylitis — PubMed: Andrographolide ankylosing spondylitis
7. Andrographolide and JBP485 / oligopeptide transporter PEPT1/PEPT2 interaction — PubMed: Andrographolide PEPT1 transporter
8. Andrographolide for psoriasis (mechanism and small clinical trials) — PubMed: Andrographolide psoriasis
9. Andrographolide attenuates LPS-induced acute lung injury (cytokine storm model) — PubMed: Andrographolide ALI
10. Andrographolide and ICAM-1 / VCAM-1 endothelial adhesion molecule suppression — PubMed: Andrographolide ICAM-1/VCAM-1

Back to Table of Contents

Research Papers: Cross-Cutting (Mechanism, Pharmacology, Safety)

1. Andrographolide pharmacokinetics and oral bioavailability in humans — PubMed: Andrographolide PK
2. Andrographis paniculata uterine stimulant activity and pregnancy contraindication — PubMed: Andrographis pregnancy safety
3. Andrographis and male fertility (rat studies) — PubMed: Andrographis male fertility
4. Andrographolide as a candidate antidiabetic agent (insulin sensitization, alpha-glucosidase inhibition) — PubMed: Andrographolide diabetes
5. Andrographolide in cancer chemoprevention (mechanism, apoptosis induction) — PubMed: Andrographolide oncology
6. Andrographolide and HIV reverse transcriptase / gp120 binding — PubMed: Andrographolide HIV
7. Andrographolide and dengue virus NS5 polymerase inhibition — PubMed: Andrographolide dengue
8. Andrographolide cardioprotection: AMPK activation and ischemia-reperfusion injury — PubMed: Andrographolide cardioprotection
9. Andrographolide neuroprotection in Parkinson's and Alzheimer's models — PubMed: Andrographolide neuroprotection
10. Andrographis paniculata adverse-effect profile and post-marketing surveillance — PubMed: Andrographis safety

Back to Table of Contents

External Authoritative Resources

• European Medicines Agency — Andrographidis Herba HMPC Monograph — the EU regulatory authority assessment of Andrographis paniculata for cold and flu
• NIH NCCIH — Herbs at a Glance
• MedlinePlus — Andrographis
• Australia TGA — Andrographis Compositional Guideline (the regulator that issued the 2015 taste-disturbance warning)
• PubMed — All research on Andrographis / andrographolide (~3,800+ papers)

Back to Table of Contents

Connections

• Andrographis (Main Page)
• Andrographis for Cold & Flu
• Andrographis for Immune Modulation
• Andrographis for Liver Protection
• Andrographis Anti-Inflammatory
• All Herbs
• Echinacea
• Elderberry
• Milk Thistle
• Turmeric
• Japanese Knotweed
• Influenza
• Pneumonia
• Sinusitis
• Arthritis
• Immune Boosting
• Vitamin C
• Vitamin D3

Back to Table of Contents